Search Within

Jacob M Ricca

Formats
  1. Journal Article (8)
  2. Meeting Abstract (8)
Groups
  1. Department of Medicine (16)
  2. Melanoma and Immunotherapeutics Service (16)
  3. Solid Tumor Oncology Division (16)
  4. GSK Faculty (14)
  5. GDMT, Medicine (12)
  6. Gynecologic Medicine Service (12)

More Groups

People
  1. Taha Merghoub (15)
  2. Jedd Wolchok (14)
  3. Dmitriy Zamarin (12)
  4. Cailian Liu (6)
  5. Levi Mark Mangarin (5)
  6. Yanyun Li (5)

More People

Years
  1. 2021 (1)
  2. 2018 (7)
  3. 2017 (7)
  4. 2016 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (5)
  2. Cancer Immunology Research (1)
  3. Cell (1)
  4. Clinical Cancer Research (1)
  5. JNCI: Journal of the National Cancer Institute (1)
  6. Journal of Clinical Investigation (1)

More Publications

Publishers
  1. Biomed Central Ltd (5)
  2. American Association for Cancer Research (2)
  3. Nature Publishing Group (2)
  4. Amer Assoc Advancement Science (1)
  5. American Society for Clinical Investigation (1)
  6. Cell Press (1)

More Publishers

Results (16)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • T cell immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants
    Meeting Abstract

    Hirschhorn, D.; Budhu, S.; Schröder, D.; Kraehenbuehl, L.; Flammar, A. L.; Chow, A.; Schulze, I.; Schad, S.; Ricca, J.; Gasmi, B.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A delicate interplay between adaptive and innate immunity caused by immunotherapy triggers tumor immunity and aseptic inflammation
    Meeting Abstract

    Hirschhorn, D.; Ricca, J.; Gasmi, B.; DeHanau, O.; Mangarin, L. M.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
    Journal of Immunology (2018)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn-Cymerman, D.; Ricca, J.; Gasmi, B.; De Henau, O.; Mangarin, L.; Budhu, S.; Li, Y.; Cortez, C.; Liu, C.; Zappasodi, R.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: Rationale for immune checkpoint blockade
    Journal Article

    Jelinic, P.; Ricca, J.; Van Oudenhove, E.; Olvera, N.; Merghoub, T.; Levine, D. A.; Zamarin, D.
    JNCI: Journal of the National Cancer Institute (2018)

    Fulltext@MSK | Save
  • Immune-active microenvironment in SCCOHT: Rationale for therapy with immune checkpoint blockade
    Meeting Abstract

    Van Oudenhove, E.; Jelinic, P.; Ricca, J.; Olvera, N.; Merghoub, T.; Levine, D. A.; Dmitriy, Z.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
    Journal Article

    Oseledchyk, A.; Ricca, J. M.; Gigoux, M.; Ko, B.; Redelman-Sidi, G.; Walther, T.; Liu, C.; Iyer, G.; Merghoub, T.; Wolchok, J. D.; more...
    Oncotarget (2018)

    Fulltext@MSK | Save
  • Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy
    Journal Article

    Ricca, J. M.; Oseledchyk, A.; Walther, T.; Liu, C.; Mangarin, L.; Merghoub, T.; Wolchok, J. D.; Zamarin, D.
    Molecular Therapy (2018)

    Fulltext@MSK | Save
  • PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
    Journal Article

    Zamarin, D.; Ricca, J. M.; Sadekova, S.; Oseledchyk, A.; Yu, Y.; Blumenschein, W. M.; Wong, J.; Gigoux, M.; Merghoub, T.; Wolchok, J. D.
    Journal of Clinical Investigation (2018)

    Fulltext@MSK | Save
  • Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells
    Journal Article

    Dai, P.; Wang, W.; Yang, N.; Serna-Tamayo, C.; Ricca, J. M.; Zamarin, D.; Shuman, S.; Merghoub, T.; Wolchok, J. D.; Deng, L.
    Science Immunology (2017)

    Fulltext@MSK | Save
  • Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy
    Meeting Abstract

    Zamarin, D.; Ricca, J.; Oseledchyk, A.; Gigoux, M.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save